Back to top
more

Vertex Pharmaceuticals (VRTX)

(Delayed Data from NSDQ)

$462.88 USD

462.88
706,669

-0.27 (-0.06%)

Updated Sep 27, 2024 04:00 PM ET

After-Market: $462.85 -0.03 (-0.01%) 7:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (87 out of 251)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Vertex Pharmaceuticals (VRTX) Gains As Market Dips: What You Should Know

Vertex Pharmaceuticals (VRTX) closed at $269.96 in the latest trading session, marking a +0.49% move from the prior day.

Vertex Pharmaceuticals (VRTX) Outpaces Stock Market Gains: What You Should Know

Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $268.64, moving +0.94% from the previous trading session.

Vertex's (VRTX) Pain Candidate Meets Goal in Two Studies

Vertex's (VRTX) two phase II proof-of-concept studies evaluating VX-548 for acute pain following abdominoplasty surgery or bunionectomy surgery meets the primary endpoint.

Novartis (NVS) Beovu Gets Label Expansion for DME in EU

Novartis (NVS) ophthalmology drug Beovus label gets expanded in EU for diabetic macular edema.

Zacks Investment Ideas feature highlights: Vertex Pharmaceuticals

Vertex Pharmaceuticals has been highlighted in this Investment Ideas article.

Bryan Hayes headshot

Why April Has the Bulls Beaming

April is the best month for the Dow since 1950 - averaging about a 2% gain.

Biogen (BIIB) Plans to Start Aduhelm Confirmatory Study in May

Biogen (BIIB) expects to start the phase IV post-marketing confirmatory study of Aduhelm for Alzheimer's disease in May 2022. The estimated completion period of the study is four years.

IGM (IGMS) Skyrockets on Collaboration Deal With Sanofi

IGM Biosciences (IGMS) inks a deal with Sanofi (SNY) to discover and develop new therapies based on its proprietary technology, which is set to target oncology, immunology and inflammation targets.

Roche (RHHBY) Late-Stage Study for ES-SCLC Fails to Meet Goal

Roche (RHHBY) phase III SKYSCRAPER-02 study assessing tiragolumab plus Tecentriq and chemotherapy as a first-line treatment for extensive-stage small cell lung cancer did not meet co-primary endpoint of progression-free survival.

Pfizer (PFE) 2nd Ulcerative Colitis Study on Etrasimod Succeeds

Pfizer's (PFE) ELEVATE UC 52 is the second phase III study on etrasimod for ulcerative colitis to have met primary and key secondary endpoints.

Vertex Pharmaceuticals (VRTX) Gains But Lags Market: What You Should Know

Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $257.98, moving +0.88% from the previous trading session.

Prothena (PRTA) IND Application Gets FDA Clearance for AD

Prothena (PRTA) application for evaluating PRX012 for the treatment of Alzheimer's disease (AD) gets FDA clearance.

Bristol Myers (BMY) Application for Opdivo With Chemo Validated

Bristol Myers (BMY) type II variation application for Opdivo in combination with chemotherapy for the neoadjuvant treatment of patients with non-small cell lung cancer gets EMA validation.

Novo Nordisk (NVO) Gets FDA Nod for Ozempic's Label Expansion

The FDA approves Novo Nordisk's (NVO) Ozempic 2.0 mg dose for the treatment of adults with type II diabetes. The medicine is now approved at 0.5 mg, 1.0 mg and 2.0 mg doses for the given indication.

Axsome (AXSM) to Acquire Jazz's Sleep Disorder Drug, Sunosi

Axsome (AXSM) inks an agreement with Jazz Pharmaceuticals to acquire the latter's new sleep disorder drug, Sunosi. The transaction is expected to close in the second quarter of 2022.

Vertex Pharmaceuticals (VRTX) Gains But Lags Market: What You Should Know

Vertex Pharmaceuticals (VRTX) closed at $255.72 in the latest trading session, marking a +0.7% move from the prior day.

Novartis (NVS) Gets Positive CHMP Opinion for Jakafi, Kymriah

Novartis (NVS) obtains positive CHMP opinion for the label expansion of Jakafi and Kymriah.

Blueprint Medicines (BPMC) Gets EU Nod for Ayvakyt in SM

The European Commission approves Blueprint Medicines' (BPMC) Ayvakyt for treating adult patients with advanced systemic mastocytosis.

Bristol (BMY) Label Expansion of Reblozyl Delayed by 3 Months

Bristol Myers (BMY) application seeking label expansion of Reblozy extended by three months by the FDA.

Mei Pharma (MEIP) to Delay Filing With FDA for Lymphoma Drug

Mei Pharma's (MEIP) FDA filing plans for zandelisib for lymphoma indication get derailed after the agency requests more clinical studies. The stock plummets in after-market trading post this news.

AstraZeneca's (AZN) Imfinzi Misses Goal in Cervical Cancer Study

AstraZeneca's (AZN) blockbuster drug Imfinzi fails to achieve progression-free survival endpoint with statistical significance in cervical cancer patients during a late-stage study.

Are You Looking for a Top Momentum Pick? Why Vertex Pharmaceuticals (VRTX) is a Great Choice

Does Vertex Pharmaceuticals (VRTX) have what it takes to be a top stock pick for momentum investors? Let's find out.

Bristol Myers (BMY) Gains 16% YTD: Will the Momentum Continue?

Bristol Myers (BMY) has put up an impressive performance so far in 2022, and the momentum should continue.

Lilly (LLY) Gets CRL from FDA for Sintilimab in Lung Cancer

Lilly (LLY) gets a complete response letter from the FDA for the biologics license application for sintilimab plus pemetrexed and platinum chemotherapy for treating first-line lung cancer.

Rezolute (RZLT) Posts Positive Data From Congenital HI Study

Rezolute (RZLT) releases favorable data from the phase IIb RIZE study on its lead candidate RZ358, currently being investigated for congenital hyperinsulinism.